Investing.com - Biomarin Pharma (NASDAQ:BMRN) reported on Wednesday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Biomarin Pharma announced earnings per share of $-0.32 on revenue of $449.81M. Analysts polled by Investing.com anticipated EPS of $-0.36 on revenue of $442.09M.
Biomarin Pharma shares are down 6.6% from the beginning of the year and are trading at $82.52 , down-from-52-week-high.They are outperforming the Nasdaq which is down 16.67% from the start of the year.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma's report follows an earnings beat by J&J on Tuesday, January 25, 2022, who reported EPS of $2.13 on revenue of $24.8B, compared to forecasts EPS of $2.12 on revenue of $25.28B.
Roche Holding ADR had matched expectations on Thursday, February 3, 2022 with fourth quarter EPS of $1.29 on revenue of $17.54B, compared to forecast for EPS of $1.29 on revenue of $17.1B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar